X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ALEMBIC PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ALEMBIC PHARMA PFIZER/
ALEMBIC PHARMA
 
P/E (TTM) x 30.8 28.9 106.7% View Chart
P/BV x 4.9 6.6 74.3% View Chart
Dividend Yield % 0.7 0.7 92.5%  

Financials

 PFIZER   ALEMBIC PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-16
ALEMBIC PHARMA
Mar-16
PFIZER/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs2,724792 344.1%   
Low Rs1,611443 363.7%   
Sales per share (Unadj.) Rs440.9167.0 264.0%  
Earnings per share (Unadj.) Rs48.738.2 127.6%  
Cash flow per share (Unadj.) Rs75.842.0 180.4%  
Dividends per share (Unadj.) Rs15.004.00 375.0%  
Dividend yield (eoy) %0.70.6 106.8%  
Book value per share (Unadj.) Rs462.984.9 545.3%  
Shares outstanding (eoy) m45.75188.52 24.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.7 133.0%   
Avg P/E ratio x44.516.2 275.2%  
P/CF ratio (eoy) x28.614.7 194.6%  
Price / Book Value ratio x4.77.3 64.4%  
Dividend payout %30.810.5 293.9%   
Avg Mkt Cap Rs m99,163116,383 85.2%   
No. of employees `0002.9NA-   
Total wages/salary Rs m2,7584,214 65.4%   
Avg. sales/employee Rs Th6,981.7NM-  
Avg. wages/employee Rs Th954.5NM-  
Avg. net profit/employee Rs Th771.1NM-  
INCOME DATA
Net Sales Rs m20,17031,487 64.1%  
Other income Rs m85755 1,556.1%   
Total revenues Rs m21,02831,542 66.7%   
Gross profit Rs m4,31010,060 42.8%  
Depreciation Rs m1,239722 171.5%   
Interest Rs m537 14.1%   
Profit before tax Rs m3,9239,356 41.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7942,160 83.1%   
Profit after tax Rs m2,2287,194 31.0%  
Gross profit margin %21.431.9 66.9%  
Effective tax rate %45.723.1 198.1%   
Net profit margin %11.022.8 48.3%  
BALANCE SHEET DATA
Current assets Rs m16,29915,066 108.2%   
Current liabilities Rs m7,5947,674 98.9%   
Net working cap to sales %43.223.5 183.8%  
Current ratio x2.12.0 109.3%  
Inventory Days Days6567 97.5%  
Debtors Days Days2641 63.4%  
Net fixed assets Rs m8,6228,237 104.7%   
Share capital Rs m458377 121.4%   
"Free" reserves Rs m20,72215,416 134.4%   
Net worth Rs m21,18016,005 132.3%   
Long term debt Rs m250-   
Total assets Rs m29,13724,594 118.5%  
Interest coverage x755.5255.2 296.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.3 54.1%   
Return on assets %7.729.4 26.1%  
Return on equity %10.544.9 23.4%  
Return on capital %19.058.7 32.4%  
Exports to sales %0.155.7 0.1%   
Imports to sales %17.510.4 167.6%   
Exports (fob) Rs m1217,551 0.1%   
Imports (cif) Rs m3,5263,283 107.4%   
Fx inflow Rs m5217,811 0.3%   
Fx outflow Rs m1405,318 2.6%   
Net fx Rs m-8812,493 -0.7%   
CASH FLOW
From Operations Rs m3,4369,304 36.9%  
From Investments Rs m-6,991-3,105 225.2%  
From Financial Activity Rs m-619-1,959 31.6%  
Net Cashflow Rs m-4,1744,240 -98.4%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 2.9 258.6%  
FIIs % 4.9 9.1 53.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 13.9 170.5%  
Shareholders   85,207 49,328 172.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   TTK HEALTHCARE  UNICHEM LAB  WYETH LTD  ELDER PHARMA  ALEMBIC LTD  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 22, 2018 (Close)

TRACK PFIZER

PFIZER - NATCO PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS